Early studies, including one from New York University published July 2, suggest Lambda, the latest variant of interest, may be a bit resistant to antibodies produced by the mRNA vaccines from Pfizer-BioNTech and Moderna, but concluded it is not by enough "to cause a significant loss of protection against infection."
Read more >